Key Insights

Highlights

Success Rate

100% trial completion (above average)

Treatment Research

2 treatments under study, led by Fecal Microbiota Transplant

Research Leaders

7 sponsors active, led by Henry Ford Hospital

Related Conditions

Often studied with 5 related conditions

Clinical Risk Assessment

Based on trial outcomes

Low Risk

Score: 25/100

Termination Rate

0.0%

0 terminated out of 2 trials

Success Rate

100.0%

+13.4% vs benchmark

Late-Stage Pipeline

0%

0 trials in Phase 3/4

Results Transparency

100%

1 of 1 completed with results

Key Signals

1 with results100% success

Data Visualizations

Phase Distribution

2Total
Not Applicable (1)
Phase 2 (1)

Trial Status

Withdrawn1
Completed1

Trial Success Rate

100.0%

Benchmark: 86.6%

Based on 1 completed trials

Clinical Trials (2)

Showing 2 of 2 trials
NCT03462459Phase 2Completed

Efficacy of Oral Vancomycin Prophylaxis for Prevention of Recurrent Clostridium Difficile Infection

NCT02968511Not ApplicableWithdrawnPrimary

EGESTA - Emergent GI Therapy for Severe, Complicated CDI Using Fecal Microbiota Transplant

Showing all 2 trials

Research Network

Common Treatments

  • Fecal Microbiota Transplant1
  • Vancomycin1

Active Sponsors

  • Henry Ford Hospital1
  • Medical College of Wisconsin1
  • Mayo Clinic1
  • Milton S. Hershey Medical Center1
  • OpenBiome1

Top Investigators

Related Conditions

  • Clostridium Difficile Infection1
  • Recurrent Clostridium Difficile Infection1
  • Cdifficile Diarrhea1
  • C Diff Colitis1
  • Cdi1

Activity Timeline